Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)

Historic Capital Expenditures for Avalo Therapeutics (AVTX) over the last 8 years, with Q1 2023 value amounting to $158000.0.

  • Avalo Therapeutics' Capital Expenditures changed N/A to $158000.0 in Q1 2023 from the same period last year, while for Dec 2023 it was $158000.0, marking a year-over-year increase of 6631.58%. This contributed to the annual value of $158000.0 for FY2023, which is 6631.58% up from last year.
  • As of Q1 2023, Avalo Therapeutics' Capital Expenditures stood at $158000.0.
  • Avalo Therapeutics' Capital Expenditures' 5-year high stood at $165969.0 during Q1 2019, with a 5-year trough of $2.0 in Q4 2019.
  • In the last 5 years, Avalo Therapeutics' Capital Expenditures had a median value of $56000.0 in 2022 and averaged $62819.4.
  • Examining YoY changes over the last 5 years, Avalo Therapeutics' Capital Expenditures showed a top increase of 125615.03% in 2019 and a maximum decrease of 9999.96% in 2019.
  • Over the past 5 years, Avalo Therapeutics' Capital Expenditures (Quarter) stood at $2.0 in 2019, then surged by 3149900.0% to $63000.0 in 2020, then plummeted by 82.54% to $11000.0 in 2021, then surged by 254.55% to $39000.0 in 2022, then soared by 305.13% to $158000.0 in 2023.
  • Its last three reported values are $158000.0 in Q1 2023, $39000.0 for Q3 2022, and $56000.0 during Q2 2022.